Description
All participants acknowledged the need for stage-selective targeting but no validated switching criteria exist. The skeptic highlighted this as a critical confound that could determine therapeutic success or failure.
Source: Debate session sess_SDA-2026-04-01-gap-001 (Analysis: SDA-2026-04-01-gap-001)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:21.295635+00:00”, “resolution_summary”: “Resolved by hypothesis h-44b1c9d415: TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer’s Disease. Supporting evidence includes debate sess_SDA-2026-04-12-gap-debate-20260410-112812-429571d2.”, “match_counts”: {“hypothesis_matches”: 5, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-44b1c9d415”, “title”: “TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer’s Disease”, “score”: 0.26, “reason”: “7 token overlaps; entity overlap: trem2”, “analysis_id”: “legacy-pre-pipeline-import-v1”, “target_gene”: “TREM2”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.827427, “confidence_score”: 0.88, “status”: “proposed”, “pubmed_evidence_ids”: [“26741508”, “28165511”, “29196612”]}, {“id”: “h-e27f712688”, “title”: “TREM2-Dependent Switch Hypothesis: TREM2 Agonism Redirects SPP1 Signaling from Destructive to Restorative”, “score”: 0.246, “reason”: “15 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062118-2cdbb0dd”, “target_gene”: “TREM2”, “target_pathway”: null, “disease”: “synaptic biology”, “composite_score”: 0.752658, “confidence_score”: 0.72, “status”: “proposed”, “pubmed_evidence_ids”: [“25292920”, “31442935”, “31902528”, “33516818”, “36747024”]}, {“id”: “h-immunity-c64967ab”, “title”: “TREM2-APOE4 Axis Drives Metabolic Inflexibility in DAM”, “score”: 0.23, “reason”: “13 token overlaps; entity overlap: trem2”, “analysis_id”: null, “target_gene”: “TREM2, APOE4, LDHA”, “target_pathway”: null, “disease”: “Alzheimer’s disease”, “composite_score”: 0.708451, “confidence_score”: 0.72, “status”: “open”, “pubmed_evidence_ids”: [“28602351”, “28993883”, “29263254”, “29861287”, “33516818”]}, {“id”: “h-dffb42d9de”, “title”: “Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin”, “score”: 0.229, “reason”: “13 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-06-gap-debate-20260406-062039-3b945972”, “target_gene”: “CHI3L1/TREM2/NRGN”, “target_pathway”: null, “disease”: “biomarkers”, “composite_score”: 0.756553, “confidence_score”: 0.68, “status”: “proposed”, “pubmed_evidence_ids”: [“29198979”, “30814620”, “32084334”, “32783918”, “33516818”]}, {“id”: “h-trem2-6a46fa2c”, “title”: “Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in Amyloid Phase, Antagonist in Tau Phase”, “score”: 0.228, “reason”: “19 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-02-gap-001”, “target_gene”: “TREM2, APOE, MAPT”, “target_pathway”: “disease staging, precision medicine”, “disease”: “Alzheimer’s disease”, “composite_score”: 0.735, “confidence_score”: 0.6, “status”: “proposed”, “pubmed_evidence_ids”: [“27986010”, “31091459”, “32949252”, “33314529”, “36002854”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-12-gap-debate-20260410-112812-429571d2”, “title”: “The theorist proposed this novel approach to enable safe agonism across disease stages, but no evidence exists for such selective pathway activation. This represents a critical gap for developing safer TREM2 therapeutics.\n\nSource: Debate session sess_SDA-2026-04-01-gap-001 (Analysis: SDA-2026-04-01-gap-001)”, “score”: 0.592, “reason”: “10 token overlaps; entity overlap: sda-2026-04-01-, trem2”, “analysis_id”: “SDA-2026-04-12-gap-debate-20260410-112812-429571d2”, “quality_score”: 0.5, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-01-gap-001”, “title”: “The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial remains contested across disease stages.”, “score”: 0.486, “reason”: “6 token overlaps; entity overlap: sda-2026-04-01-, trem2”, “analysis_id”: “SDA-2026-04-01-gap-001”, “quality_score”: 0.57, “status”: “completed”, “target_artifact_id”: “SDA-2026-04-01-gap-001”, “target_artifact_type”: “analysis”}, {“id”: “sess_SDA-2026-04-11-gap-debate-20260410-112636-141592ba”, “title”: “The debate highlighted that TREM2 therapeutic targeting remains contested across disease stages, but no clear framework exists for when to activate versus inhibit TREM2 signaling. This timing question is critical for clinical translation but remains empirically unresolved.\n\nSource: Debate session sess_SDA-2026-04-02-gap-001 (Analysis: SDA-2026-04-02-gap-001)”, “score”: 0.471, “reason”: “11 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-11-gap-debate-20260410-112636-141592ba”, “quality_score”: 0.5, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-11-gap-debate-20260410-100409-e0118210”, “title”: “The debate proposed temporal TREM2 modulation but couldn’t define when to switch from inhibition to activation phases. This fundamental timing question remains unresolved despite being critical for therapeutic success.\n\nSource: Debate session sess_SDA-2026-04-10-trem2-ad (Analysis: trem2-ad)”, “score”: 0.458, “reason”: “10 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-11-gap-debate-20260410-100409-e0118210”, “quality_score”: 0.3, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-12-gap-debate-20260410-112915-df7f8ad0”, “title”: “The debate revealed that stress granules can be both neuroprotective and pathological, but the molecular switches governing this transition remain unknown. Understanding these mechanisms is critical for timing therapeutic interventions targeting phase separation dynamics.\n\nSource: Debate session sess_SDA-2026-04-01-gap-v2-68d9c9c1 (Analysis: SDA-2026-04-01-gap-v2-68d9c9c1)”, “score”: 0.445, “reason”: “10 token overlaps; entity overlap: sda-2026-04-01-”, “analysis_id”: “SDA-2026-04-12-gap-debate-20260410-112915-df7f8ad0”, “quality_score”: 0.86, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}